Keyphrases
Multiple Myeloma
100%
Placebo-controlled Randomized Trial
100%
Clodronate
100%
Skeletal Disorders
42%
Adriamycin
28%
Cyclophosphamide
28%
Carmustine
28%
Melphalan
28%
Natural History
14%
Chemotherapy
14%
X-ray
14%
Treatment Group
14%
Subgroup Analysis
14%
Survival Benefit
14%
Median Survival
14%
5-year Survival
14%
Placebo
14%
Double-blind Placebo-controlled Trial
14%
Myeloma
14%
Myelomatosis
14%
Vertebral Fracture
14%
Working Diagnosis
14%
Medical Research Council
14%
Skeletal Fractures
14%
Skeletal Complications
14%
Spinal Fractures
14%
Prospective Clinical Trial
14%
Medicine and Dentistry
Multiple Myeloma
100%
Randomized Controlled Trial
100%
Placebo
100%
Clodronic Acid
100%
Carmustine
57%
Bone Disease
42%
Doxorubicin
28%
Cyclophosphamide
28%
Melphalan
28%
Spine Fracture
28%
Clinical Trial
14%
Subgroup Analysis
14%
Medical Research
14%
Myeloma
14%
Treatment Group
14%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Placebo
100%
Multiple Myeloma
100%
Clodronic Acid
100%
Carmustine
57%
Bone Disease
42%
Doxorubicin
28%
Cyclophosphamide
28%
Spine Fracture
28%
Melphalan
28%
Clinical Trial
14%
Chemotherapy
14%
Myeloma
14%
Treatment Group
14%
Immunology and Microbiology
Multiple Myeloma
100%
Cyclophosphamide
50%
X Ray
25%